Vulvar Neoplasms × Gastrointestinal × Clear all
NCT06638931 2026-04-15

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
28 enrolled
NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT07124000 2026-03-31

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 9 FDA
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
NCT04066894 2023-08-14

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 5 charts
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT03896958 2020-12-04

PIONEER

SpeciCare

Unknown
1,000 enrolled
NCT00066404 2020-05-13

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Abramson Cancer Center at Penn Medicine

Phase 1 Completed